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Grant FundingNeeds Parallel the
Start-Up Venture: An Analogy for
Translational Research Success
Stories of shrinking funding for biomedical optics research
and development (R&D) can lead to concerns over the poten-
tial to translate science into reality. Yet, another perspective
on this environment is that the total dollars available for trans-
lational research continues to grow every year, and there are
regional microenvironments in biomedical optics that are
thriving. As the biomedical optics community1 differentiates
into technological and application specific areas, each area
struggles with needs for sustained funding and successful
development. This editorial offers some ways to think about
how best to position a research group for funding, by exam-
ining the parallels between what is needed for translational
grants versus industry start-ups.
In the United States today, grant funding dollars are more
plentiful now than in recent years. The National Institute of
Biomedical Imaging and Bioengineering (NIBIB) payline is
currently up at the 19th percentile. An examination of the
numbers of funded grants at the National Institutes of
Health (NIH) shows an even more surprising trend. As
shown in Fig. 1, the number of funded grants in physics
and engineering has continued to grow systematically
(other than an anomalous bump from federal stimulus funding
in 2009-10) with biomedical engineering being the clear
growth leader for the last 15 years. Even more interestingly,
when these data are normalized to the total number of grants
at the NIH, as shown in Fig. 2, the funding rate of grants in
physics and engineering has actually leaped above 1.5%,
for the first time ever. This large change occurred in 2017,
and the projected numbers for 2018 show this continuing.
Still, it is widely recognized that this funding is accessible
only to those researchers who have the most competitive
edge to their translational research.
The two most critical areas of funding need are (1) the
intersection of basic and translational research, which is
largely grant funded to advance ideas into credible proof-
of-concept devices and approaches, and (2) the intersection
of applied research and industry development, which is
largely start-up funded to make a working product prototype
and test it. These two intersections are funding valleys in
which complaints abound about the inability to make it work
financially. However, for needed concepts and devices, there
are notable successes occurring every year in our field.
The needs and successes of these two areas, basic to
translational research and applied research to industry
development, are often described as fundamentally different.
However, there are important analogies that can provide
insight into making translational research more possible.
As the field of biomedical optics continues to grow, it is critical
that researchers learn the tools of R&D to create more oppor-
tunity for their research to succeed as translational and
increase their potential for funding.
The parallels between the start-up culture in industry and
the translational research culture in academic labs can be
instructive. They have several aspects in common, and the
most savvy labs have these things working for them.
The Team: Perhaps the first rule taught in preparing for a
venture capital pitch is that the team matters most. If the lead
people involved don’t have the right experience, drive, and
credibility, the pitch will be dead very quickly. The same is
true for a translational research group, where it is critical to
have a well-rounded team of people who want to work
together. Often basic researchers try the single-scientist
approach, keeping it all within their laboratory, which can
work for basic idea-driven research where innovation and
long hours are often the best way to advance research.
But in translational work, of the type funded by much of
the NIH, having a team that rounds out the translation is
critical. This will typically involve expertise starting with phys-
ics, engineering, and chemistry, but also must involve medical
specialists in the field of application, such as oncologists,
cardiologists, surgeons, dermatologists, and pathologists.
Other PhD expertise bases such as tumor biology, physiol-
ogy, or molecular biology are usually required as well, as is
biostatistics, and often also industry collaborators.
There is always a debate about whether the intellectual
integrity of the individual is more important than that of the
group, and there is certainly a lot to be said for the individual
at the intellectual level. However, as translation becomes
more of the focus, which is true for most NIH work, the
team environment is critical. Interestingly, an analysis of bio-
medical manuscript co-authorship recently showed that on
Fig. 1 The number of funded grants in engineering and physics over
the last 16 years (data from the NIH Reporter database).© 2018 Society of Photo-Optical Instrumentation Engineers (SPIE)
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average 80% of the content of a paper was attributable to the
co-authors of the work.2 The profit (p)-index was developed as
a tool to correct the h-index for the relative contributions of
co-authors in group research.
Most funded NIH proposals have a very well-rounded
team of individuals with complementary skill sets, who help
the project by making sure that decisions are being made,
even early on, that will lead to success. One indication of
this is the robust growth in the number of grants with multiple
principal investigators (multi-PI) since NIH allowed this format
to occur, with very strong uptake in physics and engineering
grants, as shown in Fig. 3. Notably, the growth in multi-PI
grants within physics and engineering is much faster than
the rest of NIH, and today rests near 26% of all funding.
While having multiple PIs is only one aspect of developing
a team, this is an indication that funding in the physical
sciences at the NIH is tied to rounding out the PI role.
Mistakes in shortcutting the team, or not fully utilizing team
members, usually leads to grant applications that are not
fundable in the NIH system.
In start-up ventures, they say the team is critical, and
this means the credibility of the team based upon training,
past accomplishments, and capabilities. The same is true for
grant funding in translational biomedical optics. There is
an urgent need to form teams across institutions. While this
may involve more consultants and contract work as budgets
get tighter relative to faculty, staff, and graduate student
salaries, ultimately strong mentors and collaborators who
have “done it before” are required for new translational
researchers to succeed.3
Talk to the Customer: Another mantra in the start-up
world is to ensure that the team talks directly to the customer,
to make sure that the solution being advanced has real value.
In industry, there must be someone willing to purchase the
solution being proposed, and it must solve a real problem
somehow such that people will pay for it. While the idea is
similar in translational research, this is very much related
to the first point about forming the team and including the
“customer” inside the team.
The team members must be present to attest to the value
of the idea. Translational research can be iterative and require
many rounds of testing ideas and having a recursive process
for this is critical. A common success plan for biomedical
engineering is for the research team to be physically located
nearby or even within a medical center, such that the process
of generating ideas, developing solutions, and obtaining feed-
back occurs in person and frequently. The best translational
research institutions have their bioengineering department
and their medical center in very close proximity, such that
there can be daily and weekly interactions between team
members. If this does not exist, it can still work, but the barrier
to keeping a quick iterative environment is higher. Talking to
the customer always matters in an enterprise where some-
thing new is being developed, and polling multiple customers
is usually critical to ensure that one’s perspective is broad
enough.
Culture is Critical: In a world where the dot-com culture
has completely shaped the way that large companies think
about innovation, it is obvious that the culture where the
work is happening must be positive, fertile, and focused on
innovation and ideas. This is very much related to the first
point about the team, but the culture here includes the attitude
and wider environment where the team exists. This positive
culture model is encouraged by leaders who reward positive
ideas and forward thinking with a balance of hard work and
an ethos to get things done.
The challenging aspect of this is that in a large well-funded
enterprise, it is easier to have this positive culture, whereas in
a small fledgling operation such as a single-PI laboratory, it
can be a challenge. Each lab can at times feel like a small
business where the lone PI has to do everything. Clustered
PIs who work in a joint laboratory or building can truly collabo-
rate and freely exchange ideas, which can create a start-up
culture where ideas are welcome, and innovation is rewarded.
Interdepartmental buildings are popping up on most
large university campuses, to help foster the rounded team
approach and an idea-focused culture. However, today, if
someone is stuck in the older world situation of a traditional
department building, this can be a major issue. Still, network-
ing exists via many social media outlets, and broadening
one’s network to include colleagues throughout the scientific
world is possible, but again requires higher energy and focus
Fig. 2 The total number of funded grants (left axis) and the percent-
age of these in engineering and physics (right axis) versus years.
Note the large increase to 1.5% along the right axis. (Data from
the NIH Reporter database.)
Fig. 3 The percentage rate of funded multi-PI directed grants in engi-
neering and physics is significantly larger than that for overall NIH
grants (data from the NIH Reporter database).
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to make it work well. More and more, broadening a research
team to include industry is also considered critical,4 and
leads to better translation beyond clinical assessment. This
can include economic viability input, as well as an infusion
of entrepreneurial perspective.
Funders Invest in Things They Care About: In the angel
funding and venture capital world, it is widely known that
investors have topical preferences where they are experts
and focus their funding decisions in these areas. Similarly,
program officers at government funding agencies specialize
in different areas, and so it is important to get to know who
is focused on which areas, and what their emphases are.
Increasingly, government funding agencies are making
decisions about what to fund, with more discretion for the
programs that demonstrably address targeted needs. As a
result, more frequently today, programs in the funding agen-
cies are choosing between moderately scored grants. This is
done either before peer review, in the form of targeted request
for applications (RFAs) or contract solicitations, or after peer
review, in the form of discretionary programmatic emphasis
decisions. Being aware of these programs is critical and
can increase the likelihood of receiving funding priority.
Additionally, funding rates vary considerably from 0% up to
100%, but with most in the 5%-20% range. Being aware of
current rates is a critical part of being smart about applying
to the most likely opportunities.
Just as pitching to the wrong investor is a waste of time for
a start-up, so is pitching in grant application to the wrong fund-
ing agency. A secret to success is to be well aware of where
the best potential funding mechanisms exist and diversifying
across them as much as is feasible.
Navigate the Valley of Death: The notorious “valley of
death” for company start-ups lies between the funding that
a company gets and the long time before they actually
make a profit selling their product. A different valley exists
between basic research and translational research,5 mostly
because of the culture differences between the two. A trans-
lational investigator must be willing to shift their work towards
translation and ensure that their innovative plans match what
is needed for the translation to succeed. In many cases, this is
not a match, and so the valley of death exists because of a
technology trajectory might not match the translational needs
exactly or it might not perform as required. Often, the expert in
a particular technology goes in search of other applications to
see if they have a prospective solution for some need. This
search process is colloquially described as “the hammer look-
ing for a nail.” While this pathway has been well traveled by
many translational researchers, there is no guarantee that
a useful application may be found for even the most interest-
ing technology.
A perceived valley of death for any new technology is
really usually just a mismatch, mistaking technology-based
research for needs-based research. To make translation
work, developers of basic biomedical optics technologies
must be flexible in searching for needs as well as solutions.
This journal recently initiated a needs-based series of articles,
called perspective reviews,6 which should be one useful
guidepost for the community of biomedical optics.7
Translational research in biomedical optics, the largest
fraction of technology in medicine, has driven the majority
of innovations in biomedical technology research and industry
R&D.8 The community needs to ensure that active motivated
researchers are well positioned to advance their work in the
coming years, keeping plans for grants focused around
innovative technologies and applications, having an eye
towards making the best team that they can create, talking
to their potential customer(s), creating a culture of innovation
throughout their network, targeting the right funding opportu-
nities, and ensuring that they balance needs with solutions.
Biomedical optics has so many successful innovative technol-
ogies, and it is critical that translational research groups get
the financial backing needed to move through to entrepre-
neurship and development.
Brian W. Pogue
Editor-in-Chief
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